Literature DB >> 15196505

Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.

S Tanganelli1, K Sandager Nielsen, L Ferraro, T Antonelli, J Kehr, R Franco, S Ferré, L F Agnati, K Fuxe, J Scheel-Krüger.   

Abstract

Behavioral and microdialysis studies have been performed on antagonistic A(2A)/D(2) interactions in animal models of Parkinson's Disease. The behavioral analysis involved studies on locomotor activity in reserpinized mice, haloperidol-induced catalepsy in rats and rotational behavior in rats with unilateral 6-OHDA lesions of the ascending DA pathways (Ungerstedt model). Dual probe microdialysis studies were indirectly performed on the striatopallidal GABA neurons by studying extracellular glutamate levels in the striatum and globus pallidus of the awake freely moving rat. The striatum was perfused with A(2A) and/or D(2) agonists via reverse microdialysis. The results show that the A(2A) antagonists SCH58261 and KF17837 can increase locomotor activity in reserpinized mice and produce contralateral rotational behavior only after administration of subthreshold doses of l-DOPA or the D(2) like agonist quinpirole. Furthermore, antagonizing the A(2A) receptor (R) reduced haloperidol induced catalepsy. The behavioral results underline the view that A(2A) antagonists act by blocking A(2A) R in A(2A)/D(2) heterodimers where A(2A) R inhibits the D(2) R transduction and D(2) inhibits the adenylate cyclase (AC) activated by A(2A) R. The microdialysis studies show that the A(2A) agonist CGS21680 striatally coperfused with the D(2) agonist quinpirole more potently counteract the D(2) agonist (quinpirole) induced reduction of pallidal glutamate levels in the DA denervated vs the control striatum indicating an enhancement of the inhibitory A(2A)/D(2) interaction. In the DA denervated but not in the control striatum the A(2A) agonist CGS21680 could strongly increase striatal glutamate levels, indicating an increased receptor signaling in the A(2A) R located on the striatal glutamate terminals, where also D(2) like R exist, here probably as D(4). Thus, the signaling of this A(2A) R may be set free by the loss of D(4) tone on the AC activated by A(2A) in this postulated A(2A)/D(4) heteromer on the glutamate terminals. Taken together, the results indicate that the antiparkinsonian actions of A(2A) antagonists probably are produced by blockade of A(2A) R in the A(2A)/D(2) heterodimers mainly located in the striatopallidal GABA neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196505     DOI: 10.1016/j.parkreldis.2004.02.015

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  28 in total

Review 1.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal.

Authors:  Taryn E Grieder; Olivier George; Huibing Tan; Susan R George; Bernard Le Foll; Steven R Laviolette; Derek van der Kooy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

Review 4.  Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.

Authors:  Kjell Fuxe; Sergi Ferré; Meritxell Canals; Maria Torvinen; Anton Terasmaa; Daniel Marcellino; Steven R Goldberg; William Staines; Kirsten X Jacobsen; Carmen Lluis; Amina S Woods; Luigi F Agnati; Rafael Franco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 5.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 6.  Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain.

Authors:  S Ferré; I Diamond; S R Goldberg; L Yao; S M O Hourani; Z L Huang; Y Urade; I Kitchen
Journal:  Prog Neurobiol       Date:  2007-05-01       Impact factor: 11.685

Review 7.  An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.

Authors:  S Ferré; C Quiroz; A S Woods; R Cunha; P Popoli; F Ciruela; C Lluis; R Franco; K Azdad; S N Schiffmann
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 8.  Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Miklós Palkovits; Alexander O Tarakanov; Francisco Ciruela; Luigi F Agnati
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

9.  On the role of adenosine (A)₂A receptors in cocaine-induced reward: a pharmacological and neurochemical analysis in rats.

Authors:  Karolina Wydra; Krystyna Gołembiowska; Agata Suder; Katarzyna Kamińska; Kjell Fuxe; Małgorzata Filip
Journal:  Psychopharmacology (Berl)       Date:  2014-07-16       Impact factor: 4.530

10.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.